![]() |
Short Contents | Full Contents | Other books NCBI |
|
Surgeon General Reports, SAMHSA TIPs, SAMHSA PEPs ![]() Signal-Averaged Electrocardiography Prepared by: Ann A. Graham, C.R.N.A., M.P.H., and Harry Handelsman, D.O. Health Technology Assessment: Number 11 U.S. Department of Health and Human Services Public Health Service Agency for Health Care Policy and Research Rockville, Maryland May 1998 AHCPR Pub. No. 98-0020 View the Medline Citation and Related Citations using PubMed AbstractSignal-averaged electrocardiography (SAECG) is a technique involving computerized analysis of segments of a standard surface electrocardiogram. It is used for detecting small electrical impulses, termed ventricular late potentials, that follow the QRS segment. They are embedded in the electrocardiogram but ordinarily obscured by skeletal muscle activity and other extraneous sources of "noise" encountered in recording a standard electrocardiogram. Ventricular late potentials in patients with cardiac abnormalities, especially coronary artery disease or following an acute myocardial infarction, are associated with an increased risk of ventricular tachyarrhythmias and sudden cardiac death. Proponents of SAECG claim that it can obviate the need for invasive techniques commonly used to identify high-risk patients for interventions that treat or prevent ventricular tachyarrhythmia and sudden death. No randomized clinical trials evaluating SAECG have been completed; data from an ongoing National Institutes of Health-sponsored clinical trial are expected to be available in 3-4 years.
The current data on SAECG show relatively consistent high negative predictive values, poor positive predictive values, and variable sensitivity and specificity when the technique is used on patients with cardiomyopathy or following a myocardial infarction.
The available evidence also indicates that combining SAECG with other tests of cardiac function is superior to using any single test for risk.
The utility of SAECG alone as an indicator of risk remains to be proven.
SAECG combined with other standard tests of risk has been demonstrated to have clinical utility in patients following an acute myocardial infarction. Other patient populations have not been conclusively shown to benefit from its use. The Center for Practice and Technology Assessment (CPTA) evaluates the risks, benefits, and clinical effectiveness of new or established medical technologies. In most instances, assessments address technologies that are being reviewed for purposes of coverage by federally funded health programs. The CPTA assessment process includes a comprehensive review of the medical literature and emphasizes broad and open participation from within and outside the Federal Government. A range of expert advice is obtained by widely publicizing the plans for conducting the assessment through publication of an announcement in the Federal Register and solicitation of input from Federal agencies, medical specialty societies, insurers, and manufacturers. The involvement of these experts helps ensure inclusion of the experienced and varying viewpoints needed to round out the data derived from individual scientific studies in the medical literature. The CPTA staff analyzed and synthesized data and information received from experts and the scientific literature. The results are reported in this assessment. Each assessment represents a detailed analysis of the risks, clinical effectiveness, and uses of new or unestablished medical technologies. If an assessment has been prepared to form the basis for a coverage decision by a federally financed health care program, it serves as the Public Health Service's recommendation to that program and is disseminated widely. The CPTA is one component of the Agency for Health Care Policy and Research (AHCPR), Public Health Service, Department of Health and Human Services. Douglas B. Kamerow, M.D., M.P.H., Director, Center for Practice and Technology
Assessment
![]() Acc:: Accuracy ART:: Arrhythmia research technology BBB:: Bundle branch block CAD:: Coronary artery disease CAST:: Cardiac arrhythmia suppression trials CFR:: Case fatality rate CHF:: Congestive heart failure CI:: Confidence interval dQRS:: Duration of the filtered QRS complex >106 ms ECG:: Electrocardiogram FD:: Frequency domain FDA:: Food and Drug Administration HCFA:: Health Care Financing Administration IDC:: Idiopathic dilated cardiomyopathy LAS:: Low amplitude signal LVEF:: Left ventricular ejection fraction LVH:: Left ventricular hypertrophy MeSH:: Medical subject heading MI:: Myocardial infarction MUGA:: Multigated acquisition NPV:: Negative predictive value NS:: Not stated NSR:: Normal sinus rhythm NYHA:: New York Heart Association PES:: Programmed electrical stimulation PPV:: Positive predictive value RMS:: Root mean square voltage during the last 40 ms of the QRS complex <25 µV RNV:: Radionuclide ventriculography SAECG:: Signal-averaged electrocardiography SD:: Sudden death 1SD:: One standard deviation Se:: Sensitivity Sp:: Specificity STA:: Spectral turbulence analysis TD:: Time domain VAT:: Ventricular activation time VF:: Ventricular fibrillation VLP:: Ventricular late potentials |